Search
Print Page   |   Contact Us   |   Sign In   |   Join Today
News & Press: Company News

CEL-SCI Receives European Patent for Multikine

Monday, July 18, 2016  
Share |
CEL-SCI has been granted a new European patent covering its investigational Phase 3 cancer immunotherapy drug Multikine* (Leucocyte Interleukin). The patent, titled “A Method Of Pre-Sensitizing Cancer Prior To Treatment With Radiation and/or Chemotherapy And A Novel Cytokine Mixture,” is not limited to any one particular type of cancer and can include multiple types of cancer.

This invention relates to a novel method for pre-sensitizing cancer cells prior to a therapeutic treatment such as chemotherapy or radiation therapy. This effect is created by CEL-SCI’s immunotherapy drug Multikine which, as part of its mode of action, induces cancerous cells to enter a proliferative cell cycle phase therapy, thereby potentially increasing their vulnerability to chemotherapy and radiation therapy.

Geert Kersten, Chief Executive Officer of CEL-SCI, said, “This European patent should protect one of the largest applications for Multikine, namely its use in combination with radiation and chemotherapy. Our ongoing Phase 3 clinical trial in head and neck cancer patients is administering Multikine therapy as part of a first-line treatment, before any other treatments and prior to surgery, followed by radiation or concurrent chemoradiotherapy.”

more Events

9/29/2016
MDMA 2016 Medical Technology Executive Forum

9/29/2016
Women Building Bio: The XX Factor

Premium Members

Membership Software Powered by YourMembership.com®  ::  Legal